The purpose of this application for a Regional Biodefense Laboratory (RBL) is to obtain funds to build a state-of-the-art biosafety level 3 (BSL-3) facility in support of the NIH/NIAID biodefense and emerging infectious diseases research agenda. The application leverages existing infectious diseases and biocontainment capabilities and expertise of the Tulane National Primate Research Center (TNPRC) to support the Regional Centers of Excellence in Biodefense and Emerging Infectious Diseases (RCE) in both Regions IV and VI. Studies in nonhuman primates will be critical to the development of therapeutics and vaccines for NIAID Category A - C agents. The TNPRC is ideally suited to meet this critical need particularly because of our expertise with infectious disease studies and model development in nonhuman primates housed at BSL-3. In addition the TNPRC already functions as a regional and national resource and thus we have the institutional culture and structure to support the RBL mission. The specific objectives of the RBL are to: 1) provide an infrastructure to support regional and national research on Category A - C agents with a focus on work requiring nonhuman primates; 2 ) provide highly integrated clinical care and laboratory investigations to the biodefense research community to obtain the maximum amount of information possible from every animal; and 3) provide oversight on experiments using animals to assure compliance with federal animal welfare and biosafety regulations. These objectives will be facilitated by the participation of the TNPRC in the nonhuman primate cores of the RCE applications from Regions IV and VI.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Construction Cooperative Agreement (UC6)
Project #
3UC6AI058609-01S2
Application #
7249946
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Lewis, Ambrose B
Project Start
2003-09-30
Project End
2009-12-31
Budget Start
2006-08-29
Budget End
2009-12-31
Support Year
1
Fiscal Year
2006
Total Cost
$3,470,129
Indirect Cost
Name
Tulane University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
053785812
City
New Orleans
State
LA
Country
United States
Zip Code
70118
Gautam, Uma S; Foreman, Taylor W; Bucsan, Allison N et al. (2018) In vivo inhibition of tryptophan catabolism reorganizes the tuberculoma and augments immune-mediated control of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 115:E62-E71
Foreman, Taylor W; Veatch, Ashley V; LoBato, Denae N et al. (2017) Nonpathologic Infection of Macaques by an Attenuated Mycobacterial Vaccine Is Not Reactivated in the Setting of HIV Co-Infection. Am J Pathol 187:2811-2820
Foreman, Taylor W; Mehra, Smriti; LoBato, Denae N et al. (2016) CD4+ T-cell-independent mechanisms suppress reactivation of latent tuberculosis in a macaque model of HIV coinfection. Proc Natl Acad Sci U S A 113:E5636-44
Dutta, Noton K; McLachlan, James; Mehra, Smriti et al. (2014) Humoral and lung immune responses to Mycobacterium tuberculosis infection in a primate model of protection. Trials Vaccinol 3:47-51
Martinez, Alejandra N; Mehra, Smriti; Kaushal, Deepak (2013) Role of interleukin 6 in innate immunity to Mycobacterium tuberculosis infection. J Infect Dis 207:1253-61
Mehra, Smriti; Alvarez, Xavier; Didier, Peter J et al. (2013) Granuloma correlates of protection against tuberculosis and mechanisms of immune modulation by Mycobacterium tuberculosis. J Infect Dis 207:1115-27
Kaushal, D; Mehra, S; Didier, P J et al. (2012) The non-human primate model of tuberculosis. J Med Primatol 41:191-201
Kaushal, Deepak (2012) Eicosanoids, prostaglandins, and the progression of tuberculosis. J Infect Dis 206:1803-5
Kaushal, Deepak; Mehra, Smriti (2012) Faithful Experimental Models of Human Mycobacterium Tuberculosis Infection. Mycobact Dis 2: